Tanabe Pharma America Transfers RADICAVA® Business to Shionogi
Tanabe Pharma America, Inc. (TPA) has made a significant decision regarding the future of its RADICAVA® product. This move supports continuous access to RADICAVA® for individuals living with ALS, while the company can concentrate on new growth opportunities and innovative treatments.
In a recent announcement, Tanabe Pharma America conveyed that both the Boards of Directors of Tanabe Pharma Corporation and Shionogi & Co., Ltd. have sanctioned the global transfer of RADICAVA®. This transaction aims to align RADICAVA® with a company dedicated to rare diseases, ensuring sustained commitment to the ALS community.
Impact on the ALS Community
RADICAVA® is a key therapy for amyotrophic lateral sclerosis (ALS), revolutionizing treatment options for patients facing this challenging condition. The decision to transfer the business to Shionogi signifies a strategic partnership aimed at enhancing the future prospects of RADICAVA®, while also providing ongoing support to patients and their families.
Leadership Insights
Yasutoshi Kawakami, the President of Tanabe Pharma America, highlighted the importance of this transaction, stating, "We are incredibly proud of the positive effect RADICAVA® has had on the ALS community. Transitioning this business allows us to maintain the reach of this critical therapy for patients and caregivers while reinforcing our commitment to develop future therapies."
Transaction Details
Until the successful completion of the transaction, all existing operations related to RADICAVA® will continue seamlessly, with Tanabe Pharma America still managing the business within North America.
The formal agreement for this transition is executed, and it is anticipated that the transfer to become a wholly owned subsidiary of Shionogi Inc. will finalize after the requisite regulatory approvals, which is expected to occur in the second quarter of the next year.
Future Operations
The transition will not interrupt the current supply chain or product availability of RADICAVA®. This change is designed to bolster Tanabe Pharma America's strategic focus on innovative therapies while ensuring patients have continued access to needed treatments.
Commitment to Innovation
As part of their ongoing mission to create hope for all facing illness, Tanabe Pharma America aims to channel efforts into enhancing its pipeline of innovative therapies. This includes addressing critical unmet medical needs through strategic partnerships and internal research.
The commitment to patients extends beyond this transaction. The company intends to prioritize innovation across its therapeutic areas, ensuring significant advancements in patient care and treatment options are on the horizon.
About RADICAVA ORS®
RADICAVA ORS® (edaravone) received FDA approval, establishing itself as a vital treatment for ALS. The recent inclusion of an oral suspension version has broadened opportunities for patient administration, circumventing the inconveniences faced with intravenous treatments.
RADICAVA ORS® is uniquely managed to suit patients' needs: taken daily for 14 days, this therapy quickly enters a drug-free phase to optimize its effectiveness. A regimented approach ensures that patients receive the best possible experience while managing their treatment.
About Tanabe Pharma America, Inc.
Tanabe Pharma America is a dedicated entity focused on providing breakthrough treatments to the North American market. Established with a firm commitment to developing innovative treatment options, TPA exemplifies a strategic approach to healthcare, ensuring that patients receive the best care possible.
For more information about their initiatives and pipeline, interested parties can connect through their company channels.
Frequently Asked Questions
What is RADICAVA® used for?
RADICAVA® is primarily used for the treatment of amyotrophic lateral sclerosis (ALS), helping to manage symptoms and improve patient quality of life.
Why is the transfer to Shionogi significant?
This transfer allows RADICAVA® to align with a company that specializes in rare diseases, ensuring enhanced attention and dedication to the needs of the ALS community.
Will patients continue to have access to RADICAVA®?
Yes, there are no anticipated changes to the supply chain or product availability, meaning patients can continue accessing RADICAVA® without interruption.
What is the focus of Tanabe Pharma America moving forward?
Tanabe Pharma America aims to enhance their pipeline of innovative therapies, focusing on unmet medical needs and improvements in patient care.
How can I find more information about Tanabe Pharma America?
For additional information, individuals can visit their official company website or engage with them through their social media platforms.
